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Abstract Two forms of soluble human type II interleukin (IL)-1
receptor (shIL-1RII) were generated, one consisting of the
complete extracellular three immunoglobulin (Ig)-like domains
and one containing only the first two N-terminal Ig-like domains.
Both forms bound IL-1L with a dissociation constant (Kd) of 200
pM and neutralized IL-1L in a bioassay. They did not bind or
neutralize IL-1K. This demonstrates that the two Ig-like domains
of shIL-1RII are sufficient to bind IL-1L with an affinity
comparable to full length shIL-1RII. This suggests that this short
form of shIL-1RII contributes to the anti-inflammatory effect of
soluble IL-1 receptors in vivo. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Interleukin-1 (IL-1) is a potent pro-in£ammatory cytokine
of the innate and adaptive immune response mediating its
biological e¡ects via speci¢c plasma membrane receptors [1].
Whereas the type I IL-1 receptor (IL-1RI) in concert with the
co-receptor IL-1R accessory protein (IL-1RAcP) is responsi-
ble for signal transduction, the non-signaling type II IL-1
receptor (IL-1RII) is involved in regulating IL-1 responsive-
ness by several di¡erent mechanisms. In its membrane form
IL-1RII can either sequester IL-1 and serve as a ligand sink
[2] or it can interact with the IL-1RAcP [3,4] and compete for
the co-receptor. The membrane form also serves as a substrate
for a cytokine-inducible ektoprotease which sheds IL-1RII
rapidly from the surface of cells [5] giving rise to a soluble
IL-1RII (sIL-1RII) [6,7] consisting of the complete extracellu-
lar part of IL-1RII. A smaller IL-1L binding protein was
reported, presumably derived from sIL-1RII by further pro-
teolytic processing. However the molecular nature and the
biological relevance of this IL-1L binding protein have not
been established [8].
Here we report that the two N-terminal immunoglobulin
(Ig)-like domains of shIL-1RII are su⁄cient to bind IL-1L
with an a⁄nity comparable to the full length 54 kDa sIL-
1RII containing all three Ig-like domains. This short sIL-
1RII neutralizes IL-1L in bioassay.
2. Materials and methods
2.1. Cloning and expression of epitope-tagged versions of human
IL-1RII
Expression plasmids for the epitope-tagged versions of shIL-1RII
were generated by PCR-cloning. The vector pFLAG-CMV-hemagglu-
tinin (HA) was derived from the cloning vector pFLAG-CMV-1 (Ko-
dak, Rochester, NY, USA) by insertion of a HA-tag (YPYDVPDYA)
followed by a stop codon between the XbaI and BamHI sites. For
pFLAG-sRII-HA the cDNA encoding amino acids Phe1^Phe335 of
hIL-1RII (three extracellular Ig-like domains) or for pFLAG-RII-
Ig1+2-HA the cDNA encoded Phe1^Glu220 (two extracellular Ig-
like domains) were inserted between the FLAG- and the HA-tag.
Di¡erent versions of hIL-1RII were expressed in 293 cells after tran-
sient transfection using a standard calcium phosphate precipitation
protocol. 40 h after transfection cells or supernatants were either
subjected to direct cross-linking with IL-1 or soluble versions of
hIL-1RII were puri¢ed.
2.2. Cross-linking of IL-1 to hIL-1RII on cells or in supernatants
In order to detect IL-1 binding molecules, cells or supernatants
were incubated with 3 ng/ml 125I-radiolabeled rhIL-1K or [125I]rhIL-
1L (NEN, Cologne, Germany) for 2 h on ice. Protein complexes were
cross-linked by addition of the homobifunctional cross-linker BS3
(Pierce/KMF, Cologne, Germany) 1 h on ice (¢nal concentration of
5 mM in phosphate-bu¡ered saline pH 7.4 (PBS)). Cells were then
washed and lysed in PBS containing 150 mM NaCl and 1% Triton X-
100 (30 min on ice). Nuclei were removed by centrifugation and cell
lysates or cross-linked supernatants analyzed by SDS^PAGE. Radio-
active bands were visualized by phosphorimaging.
2.3. Puri¢cation of epitope-tagged short and long sIL-1RII
40 h after transfection of 293 cells supernatants were collected and
concentrated 10 fold by ultra¢ltration (molecular weight cuto¡ 30
kDa for sIL-1RII (3Ig) or 10 kDa for sIL-1RII (2Ig)). shIL-1RII
molecules were puri¢ed by a⁄nity chromatography using anti-
FLAG M2 a⁄nity gel (Sigma, Deisenhofen, Germany) in PBS at
pH 7.4 and subsequently eluted with 35 mM FLAG peptide. Protein
concentrations were determined by a Bradford assay (Bio-Rad, Mu-
nich, Germany).
2.4. Binding studies with shIL-1RII (2Ig) and shIL-1RII (3Ig)
Binding studies were performed in a 96 well plate immunosorbent
assay. The HA-speci¢c monoclonal antibody (mAb) 12CA5 was
coated on P96 Maxisorp plates (NUNC, Wiesbaden, Germany) over
night, unspeci¢c binding sites were blocked by 5% BSA in PBS for 2 h.
The puri¢ed receptor molecules were captured via their C-terminal
HA-tag at room temperature for 5 h (unspeci¢c binding: PBS instead
of shIL-1RII). After three washes with PBS, di¡erent [125I]IL-1L con-
centrations were added and binding allowed for 15 h at 4‡C. Aliquots
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were removed and counted in a Q-counter to determine unbound IL-
1L. Wells were washed three times with PBS. Bound IL-1L was re-
leased by incubation with 0.1 M glycine pH 3.0 for 30 min at 37‡C
and counted in a Q-counter. All samples were done in duplicates.
Speci¢cally bound IL-1L was plotted vs. free ligand. The equilibrium
dissociation constant Kd was calculated by least square analysis of the
binding data with a one site binding model.
2.5. Bioassay to detect the neutralizing capacity of soluble human
IL-1RII forms
Neutralizing capacity of the two recombinant forms of shIL-1RII
was measured in a bioassay using murine EL-4 6.1 cells (25 000 cells/
well) which were stimulated in the presence of 50 pg/ml rhIL-1K
(kindly provided by J. Sims, Immunex, Seattle, WA, USA) or 50
pg/ml rhIL-1L (kindly provided by D. Boraschi, Dompe¤, L’Aquila,
Italy) and 2.5U1037 M A23187 (Sigma, Deisenhofen, Germany). In-
creasing concentrations of the shIL-1RII preparations were titrated in
the wells before cells were added. After 24 h murine IL-2 was mea-
sured in the supernatants using a commercial ELISA kit (Diaclone,
Besancon, France) according to the manufacturer’s instructions.
2.6. Measurement of shIL-1RII by ELISA
Soluble human IL-1RII forms were detected using a commercial kit
(RpD Systems, Wiesbaden, Germany) according to the manufactur-
er’s manual.
3. Results
3.1. Characterization of IL-1L binding proteins in 293 cells
overexpressing di¡erent forms of human IL-1RII
Two forms of IL-1L binding proteins were released into the
supernatant by 293 cells overexpressing membrane-bound IL-
1RII as detected by crosslinking with [125I]IL-1L : a large one
of 54 kDa, and a small one of 36 kDa (Fig. 1, lane 1). If 293
cells were transfected with a construct encoding a modi¢ed
IL-1RII (uIL-1RII) that cannot be cleaved between the trans-
membrane region and the juxtamembraneous Ig-like domain
[9], only an IL-1 binding molecule of 36 kDa was detected in
the supernatant (lane 2). Transfection with a plasmid encod-
ing all three extracellular Ig-like domains of IL-1RII (sIL-
1RII (3Ig), lane 3) yielded a band of 54 kDa migrating com-
parable to full length IL-1RII, while overexpressing the two
N-terminal Ig-like domains (sIL-1RII (2Ig), lane 4) resulted in
a band of 36 kDa corresponding in size to the small band
observed after expression of full length IL-1RII (lane 1) or the
modi¢ed uIL-1RII (lane 2). Supernatant of empty vector
transfected cells and medium served as negative controls
(lanes 5 and 6) whereas supernatant of cells transfected with
membrane-bound IL-1RII containing 10% FCS was used as a
positive control (lane 7).
3.2. Shedding of hIL-1RII from the cell surface results in the
loss of IL-1K binding
A band of approximately 80 kDa was identi¢ed if radio-
active IL-1K was cross-linked to 293 cells overexpressing IL-
1RII (65 kDa membrane-anchored IL-1RII covalently
coupled to 17 kDa IL-1K) (Fig. 2, lane 1). Cross-linking
with IL-1L yielded a much stronger signal of the same size
(lane 2). In supernatants of cells transfected with the expres-
sion plasmid encoding the complete extracellular part of IL-
1RII only a complex of shIL-1RII with IL-1L (lane 4) but not
with IL-1K (lane 3) was formed and cross-linked. (The shift in
the apparent molecular weight of this complex in comparison
to Fig. 1, lane 3, is due to the large amount of FCS in the
concentrated supernatants employed for these cross-linking
studies).
3.3. The a⁄nities of shIL-1RII (3Ig) and shIL-1RII (2Ig) are
comparable in binding assays
An immunosorbent binding assay was performed to com-
pare the equilibrium dissociation constants of the two forms
of shIL-1RII. The amount of ligand bound to the respective
receptor was measured at di¡erent concentrations of radio-
labeled IL-1L (Fig. 3A). An equilibrium dissociation constant
(Kd) of 186 þ 34 pM was calculated for shIL-1RII (3Ig) and
212 þ 30 pM for shIL-1RII (2Ig) being practically identical
Fig. 1. Cross-linking of supernatants from 293 cells expressing dif-
ferent forms of human IL-1RII with [125I]IL-1L. 293 cells were tran-
siently transfected with expression vectors encoding di¡erent forms
of hIL-1RII. After 40 h supernatants containing 1 or 10% FCS
were collected and incubated with 3 ng/ml [125I]IL-1L for 2 h. By
addition of 5 mM BS3 (1 h) protein complexes were cross-linked
and afterwards separated by SDS^PAGE. Radioactive bands were
visualized by phosphorimaging.
Fig. 2. Cross-linking of membrane and soluble hIL-1RII with
[125I]IL-1K or [125I]IL-1L. 293 cells were transfected with expression
vectors encoding membrane-bound or soluble human IL-1RII. After
40 h cells and 10 fold concentrated supernatants were incubated
with 3 ng/ml [125I]IL-1K or [125I]IL-1L for 2 h. Protein complexes
were cross-linked by addition of 5 mM BS3 (1 h). Proteins were
separated by SDS^PAGE and radioactive bands visualized by phos-
phorimaging.
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(Fig. 3B) (The di¡erence in saturation binding between the
two molecules is due to the di¡erent amounts of receptor
immobilized on the Maxisorp plate (Fig. 3A).) Under these
experimental conditions no binding to either of the two solu-
ble forms of hIL-1RII could be detected with IL-1K as a li-
gand (data not shown).
3.4. shIL-1RII (3Ig) and shIL-1RII (2Ig) both neutralize
IL-1L in a 24 h bioassay
The neutralizing capacity of the two recombinant shIL-
1RII molecules was investigated in a 24 h bioassay. The IL-
1L-induced IL-2 production by EL-4 6.1 cells was impaired by
the addition of increasing amounts shIL-1RII (3Ig) as well as
shIL-1RII (2Ig). In this assay full length soluble receptor (3Ig)
neutralized at slightly lower concentrations compared to shIL-
RII (2Ig) (Fig. 4A). The IL-1K-induced IL-2 production of
EL-4 cells was only slightly reduced at a high molar excess
of the two forms of shIL-1RII (Fig. 4B).
3.5. shIL-1RII (2Ig) is detectable by a commercial ELISA kit
Both forms of recombinant shIL-1RII were detected by a
commercial ELISA kit. The capture antibody used in this kit
recognized the full length shIL-1RII with the three Ig-like
domains as well as the form containing only the N-terminal
two Ig-like domains (data not shown).
4. Discussion
Membrane-anchored IL-1RII consists of three extracellular
Ig-like domains, one transmembrane spanning region, and a
short cytoplasmic rest [10]. It can be cleaved between the third
Ig-like domain and the transmembrane anchor resulting in a
soluble form (sIL-1RII) which binds preferably IL-1L. Soluble
IL-1RII was found in cell culture supernatants [6,7,11,12] and
in serum from healthy individuals [13] and patients with in-
£ammatory diseases [14^16]. It possesses anti-in£ammatory
properties by sequestering IL-1L from the circulation.
We con¢rmed that membrane-anchored IL-1RII bound
both forms of IL-1 by cross-linking IL-1K or IL-1L to hIL-
1RII. IL-1K showed a weaker cross-linking signal than IL-1L,
re£ecting the di¡erences in a⁄nity constants previously re-
Fig. 3. Binding of [125I]IL-1L to shIL-1RII (3Ig) or shIL-1RII (2Ig).
A: The preparations of recombinant sIL-1RII (3Ig) (F) of sIL-1RII
(2Ig) (E) were captured on Maxisorp plates via the precoated anti-
HA mAb 12CA5. Unspeci¢c binding was determined in absence of
shIL-1RII. After 15 h of incubation with di¡erent concentrations of
[125I]IL-1L free and bound ligand were measured in a Q-counter. Kd
was determined by least square analysis with a one site binding
model after subtraction of unspeci¢c binding and plotting of bound
vs. free ligand. B: Scatchard plot of the binding data.
Fig. 4. Neutralizing capacity of shIL-1RII (2Ig) and shIL-1RII
(3Ig). EL-4 6.1 cells were stimulated with 50 pg/ml of either rhIL-1L
(A) or rhIL-1K (B) and 2,5U1037 M A23187 in presence of di¡er-
ent concentrations of shIL-1RII (3Ig) (F) or shIL-1RII (2Ig) (E).
After 24 h murine IL-2 was measured in the supernatants by ELI-
SA.
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ported for hIL-1RII [10,17]. 293 cells transfected with full
length shIL-1RII released proteins to which only IL-1L could
be cross-linked. Thus hIL-1RII lost its ability to bind IL-1K
purely by being released from the cell surface. Furthermore,
we could not ¢nd any evidence that shIL-1RII and IL-1RAcP
interacted (Kollewe and Martin, unpublished results).
In addition to the 54 kDa shIL-1RII a smaller form of an
IL-1L binding protein had been reported [5,6,18,19]. This mol-
ecule was most likely derived from shIL-1RII by proteolytic
cleavage in the £exible hinge region between the second and
third Ig-like domains. In order to con¢rm the molecular na-
ture of this smaller shIL-1RII form and elucidate its neutral-
izing capacity, we generated two recombinant forms of the
shIL-1RII, one with all three Ig-like domains and one with
the ¢rst two N-terminal Ig-like domains. The short form of
shIL-1RII showed IL-1L binding and yielded a band in cross-
linking experiments of the expected size, proving that the two
N-terminal Ig-like domains were su⁄cient to bind IL-1L. We
compared the binding properties of the recombinant shIL-
1RII forms in an immunosorbent assay. Both forms of
shIL-1RII showed the same dissociation constant Kd of
roughly 200 pM which is in good accordance with the values
reported by others for shIL-1RII and membrane-anchored
hIL-1RII [16,17]. Also both forms neutralized IL-1L but not
IL-1K. The need for the relatively high excess of sIL-1RII
forms for complete neutralization of IL-1L may be due to
uncertainties in the calculation of biologically active recombi-
nant material. Furthermore, sIL-1RII forms have to compete
for the ligand with the membrane IL-1RI receptor complex
which can be stabilized by IL-1RAcP as reported earlier [20],
a form of stabilization not available for sIL-1RII (Kollewe
and Martin, unpublished results).
This suggests that membrane-anchored IL-1RII is ¢rst
cleaved to a 54 kDa soluble receptor containing all three Ig-
like domains. Subsequently, a second cleavage in the hinge
region between the ¢rst two N-terminal and the third Ig-like
domains results in a 36 kDa protein which maintains its IL-1L
binding and neutralization properties. As the a⁄nity con-
stants are comparable, this means that both forms of shIL-
1RII can contribute to IL-1L sequestration and participate in
down regulation of in£ammation. Although we have not for-
mally proven that the short form of the IL-1 binding protein
previously described in serum or cell culture medium is iden-
tical to our recombinant molecule, it is highly likely that this
sequential processing of hIL-1RII takes place in vivo in a
comparable fashion.
Recently, the molecular structure of a soluble hIL-1RI com-
plexed with IL-1L [21], IL-1 receptor antagonist (IL-1Ra) [22]
and an antagonistic peptide [23] was resolved by X-ray crys-
tallography. The binding site for IL-1L was mapped to an
area between the ¢rst two N-terminal Ig-like domains
[21,23]. This explains why both our molecules bind IL-1L.
From these studies it was further suggested that IL-1L
[21,23] possesses a second site of interaction in the third Ig-
like domain of IL-1RI. We did not see any di¡erence in bind-
ing of the short and long shIL-1RII, strongly suggesting that
at least in shIL-1RII the contact of IL-1L to the third Ig-like
domain is not essential for binding and does not contribute to
the binding constant. This may well be di¡erent if the receptor
is inserted in the membrane as is strongly suggested by the
major di¡erences observed between soluble and membrane-
anchored forms with respect to binding of IL-1K and inter-
action with IL-1RAcP.
As soluble hIL-1RII is regarded as a parameter for the
diagnosis of an ongoing in£ammation we questioned whether
both forms would be recognized by ELISAs. We tested one
commercially available kit (from RpD Systems). This kit was
capable of measuring both forms of hIL-1RII giving the
safety that both biologically relevant forms of soluble human
IL-1RII are detected, and the complete IL-1L binding and
neutralization capacity of IL-1RII in samples can be moni-
tored.
In summary, we show that the N-terminal two Ig-like do-
mains of soluble human IL-1RII are su⁄cient to bind and
neutralize IL-1L but not IL-1K. We propose that the hinge
region between the ¢rst two N-terminal Ig-like domains and
the third juxtamembraneous Ig-like domain contains a cleav-
age site which is used to generate a functional small form of
the soluble human IL-1RII also in vivo.
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